2-(1-(4-chlorobenzyl)-5-methyl-2-phenyl-1H-pyrrol-3-yl)-N-(3-chlorophenyl)-2-oxoacetamide | 1311376-75-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 2-(1-(4-chlorobenzyl)-5-methyl-2-phenyl-1H-pyrrol-3-yl)-N-(3-chlorophenyl)-2-oxoacetamide
• 英文别名: N-(3-chlorophenyl)-2-[1-[(4-chlorophenyl)methyl]-5-methyl-2-phenylpyrrol-3-yl]-2-oxoacetamide
• CAS: 1311376-75-6
• 化学式: C₂₆H₂₀Cl₂N₂O₂
• 分子量: 463.363
• InChiKey: AMRNVEQVRFGBSY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  51.1
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] FAAH INHIBITORS<br/>[FR] INHIBITEURS DE FAAH
  申请人：IRONWOOD PHARMACEUTICALS INC

  公开号：WO2011071996A1

  公开（公告）日：2011-06-16

  The present disclosure relates to N-benzyl pyrrole compounds of formula (I) useful as inhibitors of the enzyme Fatty Acid Amide Hydrolase (FAAH). The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the compositions in the treatment or prevention of various disorders.

  本公开涉及具有以下结构式（I）的N-苄基吡咯类化合物，可用作脂肪酸酰胺水解酶（FAAH）的抑制剂。本公开还提供了包括本公开化合物的药学上可接受的组合物，以及使用这些组合物在治疗或预防各种疾病中的方法。
• FAAH Inhibitors
  申请人：Sprott Kevin

  公开号：US20130109721A1

  公开（公告）日：2013-05-02

  The present disclosure relates to N-benzyl pyrrole compounds of formula (I) useful as inhibitors of the enzyme Fatty Acid Amide Hydrolase (FAAH). The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the compositions in the treatment or prevention of various disorders.

  本公开涉及式（I）的N-苄基吡咯化合物，其可作为脂肪酸酰胺水解酶（FAAH）的抑制剂。本公开还提供了包含本公开化合物的药学上可接受的组合物，并提供了使用这些组合物治疗或预防各种疾病的方法。
• [EN] USE OF FAAH INHIBITORS FOR TREATING ABDOMINAL, VISCERAL AND PELVIC PAIN<br/>[FR] UTILISATION D'INHIBITEURS DE FAAH POUR LE TRAITEMENT DES DOULEURS ABDOMINALES, VISCÉRALES ET PELVIENNES
  申请人：IRONWOOD PHARMACEUTICALS INC

  公开号：WO2011123719A2

  公开（公告）日：2011-10-06

  The present disclosure relates to methods of using fatty acid amide hydrolase (FAAH) inhibitors alone or in combination for the treatment or prevention of abdominal, visceral or pelvic pain. Also described herein are pharmaceutical compositions comprising a FAAH inhibitor, alone or in combination with an additional therapeutic agent for the treatment of abdominal, visceral or pelvic pain.